Exploring the Biomarkers and Potential Mechanisms of Botulinum Toxin Type A in the Treatment of Microglial Inflammatory Activation through P2X7 Receptors based on Transcriptome Sequencing
Six genes (PTPRF, Sema3b, Sema3f, CHDH, CKM, and Ky) were identified as biomarkers of microglial inflammatory activation following BoNT/A treatment. This finding may provide a valuable reference for the relief and treatment of neuropathic pain.
Authors
- Wenming Zhou
- Peng Mao (ORCID: https://orcid.org/0000-0003-2068-1344)
- Jiayang Lv
- Yi Ren (ORCID: https://orcid.org/0000-0001-6082-1378)
- Kai Zhang (ORCID: https://orcid.org/0000-0002-7408-2446)
- Yongqiang Shi
- Linna Wang (ORCID: https://orcid.org/0000-0001-9235-1577)
- Chengjun Zhang (ORCID: https://orcid.org/0000-0001-5030-7527)
- Haihong Zhang (ORCID: https://orcid.org/0000-0003-3765-1942)
- Kai‐Sheng Zhou
Institutions
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Current Pharmaceutical Design
- Published
- 2024-08-23
- DOI
- https://doi.org/10.2174/0113816128318908240730093036
- Citations
- 1
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.37